Loading...
•
Sep 30, 2022
Vera Q3 2022 Earnings Report
Vera Therapeutics reported financial results for the quarter ended September 30, 2022.
Key Takeaways
Vera Therapeutics reported a net loss of $24.7 million for the third quarter of 2022. The company's cash, cash equivalents, and marketable securities totaled $114.4 million as of September 30, 2022. The pivotal Phase 3 COMPASS clinical trial of atacicept in lupus nephritis was initiated.
Phase 2b ORIGIN clinical trial of atacicept in IgA nephropathy (IgAN) topline data planned to be presented in early Q1 2023
Initiated the pivotal Phase 3 COMPASS clinical trial of atacicept in lupus nephritis
Presented positive final results from the Phase 2 trial of MAU868 versus placebo in kidney transplant recipients with reactivated BKV infection during ASN Kidney Week 2022
Strong balance sheet with $114.4 million in cash, cash equivalents, and marketable securities as of September 30, 2022
Forward Guidance
Vera Therapeutics plans to announce topline data from the Phase 2b ORIGIN clinical trial of atacicept in IgAN in early first quarter of 2023 and expects to initiate a Phase 2b or Phase 3 clinical trial of MAU868 in BK viremia in kidney transplant recipients in 2023.
Positive Outlook
- Plan to announce topline data from the Phase 2b ORIGIN clinical trial of atacicept in IgAN in early first quarter of 2023
- Expect to initiate a Phase 2b or Phase 3 clinical trial of MAU868 in BK viremia in kidney transplant recipients in 2023
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...